Xpress Biologics
Xpress Biologics is a company that provides a wide range of services in biologics production, including plasmid DNA, recombinant proteins, and antibody fragments. They serve vaccine, therapeutics, and diagnostic markets, offering development, manufacturing, and quality control services. They also participate in industry events and have developed proprietary production processes to support research and clinical applications.
Industries
Nr. of Employees
small (1-50)
Xpress Biologics
Accessia Pharma site, Avenue du Parc Industriel, 89, 4041 Milmort, BELGIQUE
Products
Recombinant CRM197 (carrier protein)
Recombinant non-toxic diphtheria-toxin-derived carrier protein produced in microbial expression systems for use as a carrier in conjugate vaccines; offered in R&D, GLP and planned GMP grades with defined purity and impurity specifications.
Recombinant CRM197 (carrier protein)
Recombinant non-toxic diphtheria-toxin-derived carrier protein produced in microbial expression systems for use as a carrier in conjugate vaccines; offered in R&D, GLP and planned GMP grades with defined purity and impurity specifications.
Services
Contract production and purification of plasmid DNA across R&D, High-Quality and planned GMP grades with dedicated QC and deliverables (CoA, batch records, cell banks).
Microbial recombinant protein development and manufacturing including expression system design, upstream fermentation, downstream purification and analytical characterization for R&D and preclinical material.
Development and production of various antibody fragment formats (Fab, minibody, diabody, nanobody) using microbial expression platforms with USP, DSP and QC development.
Support for preclinical production and operational management of clinical trial material and associated activities under a one-stop-shop model.
Development and implementation of analytical methods required for identity, purity, potency and impurity testing (HPLC, ELISA, WB, MS, endotoxin, qPCR, bioburden).
Contract production and purification of plasmid DNA across R&D, High-Quality and planned GMP grades with dedicated QC and deliverables (CoA, batch records, cell banks).
Microbial recombinant protein development and manufacturing including expression system design, upstream fermentation, downstream purification and analytical characterization for R&D and preclinical material.
Development and production of various antibody fragment formats (Fab, minibody, diabody, nanobody) using microbial expression platforms with USP, DSP and QC development.
Support for preclinical production and operational management of clinical trial material and associated activities under a one-stop-shop model.
Development and implementation of analytical methods required for identity, purity, potency and impurity testing (HPLC, ELISA, WB, MS, endotoxin, qPCR, bioburden).
Expertise Areas
- Plasmid manufacturing for gene therapy and DNA vaccines
- Microbial recombinant protein production (E. coli and Pichia pastoris)
- Antibody fragment production and reformating
- Bioprocess development and scale-up (fermentation and purification)
Key Technologies
- High cell-density fermentation
- Fed-batch bioprocessing
- E. coli expression systems
- Pichia pastoris expression systems
News & Updates
Participation in BIO 2018 industry event.
Participation in the 23rd annual international partnering conference.
Participation in BioFIT 2017 in Strasbourg, France.
Participation in the European Antibody Congress.
Participation in BIO 2018 industry event.
Participation in the 23rd annual international partnering conference.
Participation in BioFIT 2017 in Strasbourg, France.
Participation in the European Antibody Congress.